

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number 09/855,320
Filing Date May 14, 2001
First Named Inventor Bayer, Robert J.
Group Art Unit 1646
Examiner Name
Attorney Docket Number 019957-014110US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
mm	BA	WO	96/40881		The General Hospital Corporation	12/19/96	—	
mm	BB	WO	98/31826		Cytel Corporation	07/23/98	—	

Examiner Signature

mm

Date Considered

9/24/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1312637 v1

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheets 2 of 2

Complete if Known

Application Number	09/855,320
Filing Date	May 14, 2001
First Named Inventor	Bayer, Robert J.
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	019957-014110US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DOML	1	COSTA, et al, "Stable Expression of the Golgi Form and Secretory Variants of Human Fucosyltransferase III from BHK-21 Cells, The Journal of Biological Chemistry (1997); 272 (17) 11613-11621 (USA)	
	2	DINTER, et al "Glycosylation engineering in Chinese hamster ovary cells using tricistronic vectors," Biotechnology Letters 22: (2000) 25-30	
DOML	3	WANG, et al "Identification of a GDP-L-fucose: polypeptide fucosyltransferase and enzymatic addition of O-linked fucose to EGF domains," Glycobiology (1996): 6(8) 837-842	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1312637 v1

Please type a plus sign (+) inside this box

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/855,320
Filing Date	May 14, 2001
First Named Inventor	Bayer, Robert J.
Group Art Unit	1420
Examiner Name	
Attorney Docket Number	019957-014110US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm2	AE	Dumas, <i>et al.</i> "Enzymatic Synthesis of Sialyl Le ^x and Derivatives Based on a Recombinant Fucosyltransferase" <i>Bioorganic & Medicinal Chemistry Letters</i> (1991) Vol. 1(8), pp. 425-428. ✓	<input type="checkbox"/>
	AF	Ichikawa, <i>et al.</i> "Chemical-Enzymatic Synthesis and Conformational Analysis of Sialyl Lewis x and Derivatives" <i>J. Am. Chem. Soc.</i> (1992) Vol. 114, pp. 9283-9298. ✓	<input type="checkbox"/>
	AG	Kaneko, <i>et al.</i> "α1,3-Fucosyltransferase IX (Fuc-TIX) Is Very Highly Conserved Between Human and Mouse; Molecular Cloning, Characterization and Tissue Distribution of Human Fuc-TIX" <i>FEBS Letters</i> (1999) Vol. 425, p. 237-242. ✓	<input type="checkbox"/>
	AH	Kaneko, <i>et al.</i> "Assignment of the Human α 1,3-fucosyltransferase IX gene (FUT9) to Chromosome Band 6q16 by <i>In Situ</i> Hybridization" <i>Cytogenetics Cell and Cell Genetics</i> (1999) Vol. 86, pp. 329-330. ✓	<input type="checkbox"/>
	AI	Kimura, <i>et al.</i> "Reconstitution of Functional L-selectin Ligands on a Cultured Human Endothelial Cell Line by Cotransfection of α1→3 Fucosyltransferase VII and Newly Cloned GlcNAcβ-6-sulfotransferase cDNA" <i>Proc. Natl. Acad. Sci. USA</i> (April 1999) Vol. 96, pp. 4530-4535. ✓	<input type="checkbox"/>
	AJ	Kukowska-Latallo, <i>et al.</i> "A Cloned Human cDNA Determines Expression of a Mouse Stage-Specific Embryonic Antigen and the Lewis Blood Group α(1,3/1,4)fucosyltransferase" <i>Genes & Development</i> (1990) Vol. 4, pp. 1288-1303. ✓	<input type="checkbox"/>
	AK	Leiter, <i>et al.</i> "Purification, cDNA Cloning, and Expression of GDP-L-Fuc:Asn-linked GLcNAc α1,3 Fucosyltransferase from Mung Beans" <i>The Journal of Biological Chemistry</i> (July 1999) Vol. 274(31), pp. 21830-21839. ✓	<input type="checkbox"/>
	AL	Mollicone, <i>et al.</i> "Acceptor Specificity and Tissue Distribution of Three Human α-3 Fucosyltransferases" <i>Eur. J. Biochem. FEBS</i> (1990) Vol. 191, pp. 169-176. ✓	<input type="checkbox"/>
	AM	Nunez, <i>et al.</i> "The Synthesis and Characterization of α - and β - L-fucopyranosyl phosphates and GDP fucose" <i>Can. J. Chem</i> (1981) Vol. 59, pp. 2086-2095. ✓	<input type="checkbox"/>
mm2	AN	Palic, <i>et al.</i> "Enzymic Synthesis of Oligosaccharides Terminating in the Tumor-Associated Sialyl-Lewis-a Determinant" <i>Carbohydrate Research</i> (1989) Vol. 190, pp. 1-11. ✓	<input type="checkbox"/>

RECEIVED

SEP 24 2001

TC 1700

Examiner Signature

mm2

Date Considered

9/24/02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1267079 v1

Please type a plus sign (+) inside this box

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/855,320
Filing Date	May 14, 2001
First Named Inventor	Bayer, Robert J.
Group Art Unit	1420
Examiner Name	
Attorney Docket Number	019957-014110US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm2	AO	Prieels, <i>et al.</i> "Co-purification of the Lewis Blood Group N-Acetylglucosaminide α 1 \rightarrow 4Fucosyltransferase and an N-Acetylglucosaminide α 1 \rightarrow 3Fucosyltransferase from Human Milk" <i>J. of Biological Chemistry</i> (October 1981) Vol. 256(20), pp. 10456-10463. ✓	<input type="checkbox"/>
	AP	Rasko, <i>et al.</i> "Cloning and Characterization of the α (1,3/4) Fucosyltransferase of <i>Helicobacter pylori</i> " <i>J. of Biological Chemistry</i> (February 2000) Vol. 275(7), pp. 4988-4994. ✓	<input type="checkbox"/>
	AQ	Staudacher, Erika "α1,3Fucosyltransferase" <i>Trends in Glycoscience and Glycotechnology</i> (November 1996) Vol. 8(44), pp. 391-408. ✓	<input type="checkbox"/>
	AR	Trottein, <i>et al.</i> "Molecular Cloning of a Putative α3-fucosyltransferase from <i>Schistosoma mansoni</i> " <i>Molecular and Biochemical Parasitology</i> (2000) Vol. 107, pp.279-287. ✓	<input type="checkbox"/>
	AS	van Tetering, <i>et al.</i> "Characterization of a Core α1 \rightarrow 3Fucosyltransferase from the Snail <i>Lymnaea stagnalis</i> that is Involved in the Synthesis of Complex-type N-glycans" <i>FEBS Letters</i> (1999) vol. 461, pp. 311-314. ✓	<input type="checkbox"/>
mm2	AT	Wang, <i>et al.</i> "Novel <i>Helicobacter pylori</i> α1,2-fucosyltransferase, a Key Enzyme in the Synthesis of Lewis Antigens" <i>Microbiology</i> (1999) Vol. 145, pp. 3245-3253.	<input type="checkbox"/>

RECEIVED

SEP 24 2001

TC 1700

Examiner Signature	mm2	Date Considered	9/24/02
--------------------	-----	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1267079 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	09/855,320
Filing Date	May 14, 2001
First Named Inventor	Bayer, Robert J.
Group Art Unit	1420
Examiner Name	
Attorney Docket Number	019957-014110US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

SF 1267079 v1